Market Closed -
Nasdaq
16:00:00 2024-06-28 EDT
|
5-day change
|
1st Jan Change
|
1.19
USD
|
+4.39%
|
|
-2.46%
|
+12.26%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
20.95
|
54.97
|
87.85
|
48.59
|
33.99
|
68.73
|
-
|
-
|
Enterprise Value (EV)
1 |
20.95
|
54.97
|
87.85
|
48.59
|
33.99
|
68.73
|
68.73
|
68.73
|
P/E ratio
|
-0.39
x
|
-2.75
x
|
-4.13
x
|
-1.11
x
|
-0.79
x
|
-1.71
x
|
-1.95
x
|
-2.29
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
28.9
x
|
11.6
x
|
48.6
x
|
-
|
-
|
-
|
4.18
x
|
EV / Revenue
|
-
|
28.9
x
|
11.6
x
|
48.6
x
|
-
|
-
|
-
|
4.18
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-3,376,136
x
|
-1,404,975
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
4,872
|
9,462
|
15,886
|
20,588
|
32,062
|
57,755
|
-
|
-
|
Reference price
2 |
4.300
|
5.810
|
5.530
|
2.360
|
1.060
|
1.190
|
1.190
|
1.190
|
Announcement Date
|
3/13/20
|
3/23/21
|
3/31/22
|
3/16/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
1.9
|
7.6
|
1
|
-
|
-
|
-
|
16.42
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-17.21
|
-16.98
|
-25.29
|
-41.95
|
-37.87
|
-37.63
|
-38.67
|
-34.46
|
Operating Margin
|
-
|
-893.79%
|
-332.82%
|
-4,195%
|
-
|
-
|
-
|
-209.81%
|
Earnings before Tax (EBT)
1 |
-19.37
|
-16.77
|
-20.94
|
-41.3
|
-37.34
|
-37.37
|
-38.46
|
-34.19
|
Net income
1 |
-27.95
|
-16.84
|
-20.7
|
-41.3
|
-37.34
|
-37.37
|
-38.46
|
-34.19
|
Net margin
|
-
|
-886.05%
|
-272.36%
|
-4,130.1%
|
-
|
-
|
-
|
-208.18%
|
EPS
2 |
-10.92
|
-2.110
|
-1.340
|
-2.130
|
-1.340
|
-0.6967
|
-0.6100
|
-0.5200
|
Free Cash Flow
|
-
|
-
|
-26.02
|
-34.58
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-342.37%
|
-3,458.3%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/13/20
|
3/23/21
|
3/31/22
|
3/16/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
1
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-11.62
|
-6.735
|
-8.623
|
-7.146
|
-9.446
|
-11.28
|
-8.84
|
-9.361
|
-8.177
|
-9.645
|
-9.502
|
-9.24
|
-9.367
|
-
|
-
|
Operating Margin
|
-
|
-673.5%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-6.835
|
-16.74
|
-8.414
|
-7.022
|
-9.121
|
-11.1
|
-8.84
|
-9.267
|
-8.136
|
-9.566
|
-9.447
|
-9.204
|
-9.275
|
-
|
-
|
Net income
1 |
-6.598
|
-16.74
|
-8.414
|
-7.022
|
-9.121
|
-11.1
|
-8.84
|
-9.267
|
-8.136
|
-9.566
|
-9.447
|
-9.204
|
-9.275
|
-
|
-
|
Net margin
|
-
|
-1,674.4%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.4200
|
-1.050
|
-0.4100
|
-0.3400
|
-0.4300
|
-0.4700
|
-0.3100
|
-0.3300
|
-0.2500
|
-0.2100
|
-0.1733
|
-0.1667
|
-0.1533
|
-0.1300
|
-0.1300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/31/22
|
5/12/22
|
8/11/22
|
11/14/22
|
3/16/23
|
5/11/23
|
8/10/23
|
11/9/23
|
3/28/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-26
|
-34.6
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/13/20
|
3/23/21
|
3/31/22
|
3/16/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
1.19
USD Average target price
5.833
USD Spread / Average Target +390.20% Consensus |
1st Jan change
|
Capi.
|
---|
| +12.26% | 68.73M | | +15.20% | 121B | | +19.67% | 113B | | +18.95% | 26.02B | | -23.86% | 19.39B | | -19.03% | 15.91B | | -20.90% | 15.09B | | -46.14% | 15.06B | | +63.85% | 14.93B | | +4.49% | 13.85B |
Bio Therapeutic Drugs
|